Emil Zhang

October 30, 2022

Emil Zhang is the Director of European IPR Department, Huawei, where he has specialized in IP, contract, litigation, and legal management for many years. He has participated in high profile company-level litigations, including EU trade defense investigation (anti-dumping, anti-subsidies, safeguard) and major patent litigation. He has led the company’s patent infringement assertions across the world as well as company-level cooperation projects with major industrial peers, customers, and suppliers. He focuses now more on IP related litigation, patent licensing program and trade defense investigations.

The United States Cannot Afford Disarray as China Strengthens Its Biopharmaceutical Industry

March 18, 2025

By Sujai Shivakumar, Charles Wessner, and Julie Heng For years, China has played a leading role in manufacturing active pharmaceutical ingredients and generic drugs. While securing the supply chain for active pharmaceutical ingredients is increasingly recognized as a national security priority by policymakers, China’s growing role in biotechnological innovation has

Explainer: A Brief History of the International IP Regime

February 19, 2025

By Julie Heng, Arrizka Faida, and Chris Borges In a globalized economy, businesses rely on rules protecting intellectual property (IP) to safeguard their ideas and products against counterfeiting, piracy, and theft and to forge international partnerships. To this end, the United States and its partners have long invested in a system of multilateral treaties and international

ChinaTalk: Innovation Emergency with Trump 1.0’s Patent Director

February 19, 2025

On February 19th, CSIS Senior Adviser Andrei Iancu appeared on the ChinaTalk podcast to discuss how patents influence emerging technology innovation, how far AI and DOGE could push the current U.S. IP regime, if it matters that China issues more patents than the United States, and more. Listen to the